Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/11/2025 ,inter alia, to consider and approve the proposal for alteration in ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Titan Biotech Ltd has informed BSE that its Board of Directors will meet on Saturday, 29 November 2025, to consider and approve a proposal for alteration of share capital through sub-division/split of existing equity shares with a face value of Rs. 10 each, subject to shareholder and other necessary approvals. The proposal is currently only an intent—the Board will evaluate the split ratio and terms at the meeting, and shareholders will need to vote on it separately. The trading window for designated persons has been closed from 25 November 2025 until 48 hours after the Board meeting outcome is declared, in line with insider trading regulations.
If approved, a stock split would lower the per-share price of Titan Biotech, potentially improving liquidity and retail accessibility, though it does not change the company's overall valuation. Short-term price movement is often positive on stock-split news due to increased affordability.